News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2015Sites scheduling additional patients in HPPI’s study of proposed treatment for basal cell carcinoma nevus syndrome
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (September 29, 2015) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Aug 21, 2015Enrollment commenced in HPPI’s Phase II(b) study of SUBATM-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – August 21, 2015 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
May 18, 2015HedgePath to shortly commence Phase II(b) skin cancer trial using Mayne Pharma’s SUBATM-Itraconazole
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (May 18, 2015) – HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers,...
-
Dec 16, 2014HPPI to commence Phase IIb study in first quarter 2015 of SUBATM-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – December 16, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
Nov 18, 2014Company plans to commence clinical development of SUBA®-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – November 18, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
Jun 26, 2014Stefan Cross, Dr. Dana Ono and Mark Watson add significant biotechnology, capital markets and public accounting expertise to HPPI’s board of directors
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 26, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers,...
-
Jun 25, 2014$1.5 million in proceeds to fund 2014 commencement of HPPI’s clinical development program for repurposing the approved anti-fungal drug itraconazole for the treatment of cancer, initially for the treatment of Basal Cell Carcinoma Nevus Syndrome
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 25, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers,...
-
Jan 8, 2014Presentation to be held at Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square, San Francisco
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (January 8, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Sep 10, 2013Acquires Exclusive U.S. Rights for use of Mayne Pharma’s SUBA™ Itraconazole for treatment of cancer
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (September 10, 2013) – HedgePath Pharmaceuticals, Inc. (OTCPink:HPPI) (HPPI) announced today that it has signed an exclusive Supply and License...
-
Aug 9, 2013Commences Trading on the OTC Pink Market Under the Symbol “HPPI”
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA -- (August 19, 2013) – HedgePath Pharmaceuticals, Inc. (OTCPink:HPPI) (HPPI) announced today that it has completed a series of transactions to effectuate...